[Controlled clinical trial of parsalmide, a drug with analgesic and anti-inflammatory activity].
A controlled clinical trial of the anti-inflammatory, analgesic, muscle-relaxing and anxiolytic activity of a new compound (parsalmide) was compared with that of phenybutazone in 40 patients with acute or exacerbated inflammatory or degenerative processes randomly distributed into two treatment groups. Parsalmide was more effective in the relief of joint swelling and anxiety and gave better motility. On an overall evaluation, however, it was on a par with phenylbutazone. Treatment had to be suspended in two cases treated with phenylbutasone, whereas tolerance was good with parsalmide and no suspensions were required.
D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006801:Humans; D007592:Joint Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010653:Phenylbutazone / Q000627:therapeutic use; D013924:Thrombophlebitis / Q000188:drug therapy
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001549:Benzamides; D010653:Phenylbutazone
Sperimentazione clinica controllata di parsalmide, farmaco ad attività analgesica ed antiinfiammatoria